 reuters    u s  democrat senator claire mccaskill on thursday asked kaleo pharmaceuticals to justify the more than  percent surge in the price of its device to treat painkiller overdoses  becoming the second senator to question evzio s    price tag  evzio contains the overdose reversing drug naloxone and can be used in emergencies by people without medical training  privately held kaleo has raised the price of a twin pack to     from   in   according to a kaiser health news report   bit ly   the concerns over evzio s price comes at a time when pharmaceutical companies are facing intense scrutiny over  price gouging   and as lawmakers struggle with the epidemic of opioid abuse  the centers for disease control and prevention estimates at least  americans succumb every day to opioid overdose  which experts partly blame on unrestricted painkiller prescriptions   at a time when congress has worked to expand access to naloxone products and to assist state and local communities to equip first responders with this life saving drug  this startling price hike is very concerning   mccaskill said in a letter to kaleo chief executive spencer williamson   bit ly   the letter  which was signed by  u s  senators  asked kaleo for information on evzio s price structure and why the company chose to adjust prices   we received the letter from the senators and are in communication with them to ensure all questions are addressed   williamson told reuters in an e mailed statement  democrat senator amy klobuchar sent kaleo a letter earlier this month  voicing similar concerns  williamson said that americans with commercial insurance and a prescription could get evzio  which was approved in   for no out of pocket cost  or for   if they paid cash  he added that people without insurance and with household income under    could get evzio for no out of pocket cost  kaleo s other product is auvi q  an emergency allergy auto injector that is a rival to mylan nv s epipen  which came under intense criticism last year for its high price  kaleo said last month that it would offer auvi q at no cost to many consumers  but set a list price   to be used as the benchmark cost to insurance companies   at a whopping     